CAS: 677331-12-3

Applications A potent inhibitor of β-catenin-responsive transcription (CRT) (IC50 = 40.3 nM in assays of Wnt pathway activity). Studies suggest that it may directly influence the interaction between β-catenin and TCF4. It induces marked G0/G1 cell cycle arrest in HCT-116 and HT29 cell lines. References Gonsalves, F.C. et al.: Proc. Natl. Acad. Sci. USA, 108, 5954 (2011); Watanabe, K. et al.: Proc. Natl. Acad. Sci. USA, 108, 5929 (2011);

iCRT 14 is a novel potent inhibitor of β-catenin-responsive transcription (CRT)(IC50= 40.3 nM in assays of Wnt pathway activity).

iCRT 14

iCRT-14 is a drug that has been shown to be effective in the treatment of a number of different diseases. It is a pluripotent cell therapy that is derived from skin cells which are grown and then induced to differentiate into other types of cells, such as cardiac cells. iCRT-14 has been shown to be capable of reversing the progression of some types of breast cancer by activating transcription-polymerase chain reaction (PCR) and increasing epidermal growth factor levels. The activation of cell signaling pathways, such as c-jun phosphorylation, also plays a role in iCRT-14's effect on cancer cells.